Curated News
By: NewsRamp Editorial Staff
September 28, 2026
NanoViricides Begins Phase II Trial of NV-387 for Ebola in DRC
TLDR
- NanoViricides advances NV-387 into Phase II Ebola trial, positioning NNVC ahead in broad-spectrum antiviral development.
- NanoViricides enrolls patients in DRC for Phase IIA, establishing safe dosing protocol for NV-387 oral gummies.
- NanoViricides' trial in DRC offers hope for Ebola treatment, potentially improving global health outcomes.
- NanoViricides tests oral gummies for Ebola in DRC, a novel approach to antiviral therapy.
Impact - Why it Matters
This news matters because it represents a critical step forward in the fight against Ebola, a highly lethal virus with limited treatment options. The initiation of a Phase II clinical trial for NV-387 Oral Gummies in the Democratic Republic of Congo, a region recurrently affected by Ebola outbreaks, underscores the urgent need for effective, broad-spectrum antiviral therapies. If successful, NV-387 could provide a much-needed oral treatment option that is easy to administer in resource-limited settings, potentially saving countless lives. Moreover, NanoViricides' platform technology, if validated, could be applied to a wide range of other viral diseases, including COVID-19, influenza, and RSV, addressing significant global health challenges. Investors and public health officials alike should monitor this trial's progress, as positive results could herald a new era in antiviral therapeutics and significantly impact NanoViricides' market position.
Summary
NanoViricides, Inc. (NYSE American: NNVC) has announced a significant milestone: its Phase II clinical trial evaluating NV-387 Oral Gummies as a treatment for Bundibugyo Ebolavirus and other Ebola viruses has begun enrolling and dosing patients at an Ebola Treatment Center in the Ituri province of the Democratic Republic of Congo (DRC). The Phase IIA portion, which started around September 23, is designed to establish a safe and well-tolerated dosing protocol for NV-387. This protocol will then be used in the Phase IIB portion, which will evaluate the drug's safety, tolerability, and effectiveness. The trial is registered in the Pan African Clinical Trials Registry under identification number PACTR202608748555077.
NanoViricides is a clinical-stage company creating special purpose nanomaterials for antiviral therapy. Its novel nanoviricide™ class of drug candidates is based on intellectual property and technology from TheraCour Pharma, Inc. The company's lead drug candidate, NV-387, is a broad-spectrum antiviral being developed for RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox and Measles. Other advanced candidates include NV-HHV-1 for Shingles and NV-CoV-2 for COVID-19. The company's business model focuses on licensing technology from TheraCour Pharma for specific antiviral applications. For more details, visit www.nanoviricides.com. The latest news and updates relating to NNVC are available in the company's newsroom at https://ibn.fm/NNVC.
The announcement was distributed through MissionIR, a specialized communications platform that is part of the Dynamic Brand Portfolio @ IBN, which provides access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution, and a full array of tailored corporate communications solutions.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, NanoViricides Begins Phase II Trial of NV-387 for Ebola in DRC
